Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial

Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps... Multivariate survival analyses, visual observations, and receiver operating characteristic comparisons helped demonstrate that, compared with conventional segmentation, contrast-enhanced T1-weighted subtraction maps of contrast-enhancing lesions produce better stratification of high- and low-risk patients treated with bevacizumab and therefore should be used in future clinical trials involving evaluation of antiangiogenic therapies in brain tumors. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Radiology Radiological Society of North America, Inc.

Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial

Download PDF
11 pages

Loading next page...
 
/lp/radiological-society-of-north-america-inc/recurrent-glioblastoma-treated-with-bevacizumab-contrast-enhanced-t1-07dzfeghH5

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Radiological Society of North America, Inc.
Copyright
2014 by the Radiological Society of North America, Inc.
Subject
Original Research
ISSN
1527-1315
eISSN
0033-8419
DOI
10.1148/radiol.13131305
pmid
24475840
Publisher site
See Article on Publisher Site

Abstract

Multivariate survival analyses, visual observations, and receiver operating characteristic comparisons helped demonstrate that, compared with conventional segmentation, contrast-enhanced T1-weighted subtraction maps of contrast-enhancing lesions produce better stratification of high- and low-risk patients treated with bevacizumab and therefore should be used in future clinical trials involving evaluation of antiangiogenic therapies in brain tumors.

Journal

Radiology – Radiological Society of North America, Inc.

Published: Apr 27, 2014

There are no references for this article.